ZRT Laboratory has introduced two new SARS-CoV-2 antibody detection products that use dried blood spot testing.
The tests require a healthcare professional to perform a finger prick and place a few blood drops onto a filter card. Once dry, the card is shipped with coolants to ZRT's CLIA-certified laboratory for testing. One was developed by Euroimmun and targets the SARS-CoV-2 spike-S1 protein; this product has an emergency use authorization in the U.S. The other was developed by Epitope Diagnostic and targets the nucleocapsid protein; emergency clearance in the U.S. is pending.
ZRT noted that it has more than 15 years' experience developing finger-stick dried blood spot tests.